Aflibercept is a recombinant fusion protein designed to inhibit vascular endothelial growth factor (VEGF), a key driver of pathological blood vessel formation. It is clinically approved for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Aflibercept consists of the extracellular binding domains of human VEGF receptors 1 and 2 fused to the Fc region of human IgG1, enabling it to function as a decoy receptor.
By binding to VEGF-A and placental growth factor (PlGF), aflibercept prevents these ligands from activating VEGFR-1 and VEGFR-2 on the surface of endothelial cells. This inhibition reduces abnormal neovascularization and vascular permeability, which are hallmarks of AMD and other retinal disorders. In oncology, aflibercept is also used as part of combination therapy for metastatic colorectal cancer, where it helps restrict tumor angiogenesis.
In both research and clinical settings, the monitoring of aflibercept trough levels and the development of anti-drug antibodies is increasingly important. These measurements guide therapeutic decisions, enabling clinicians to adjust dosing regimens or consider alternative therapies when necessary, thereby improving patient outcomes and minimizing resistance or adverse reactions.
This product is manufactured in Turkey by Matriks Biotek.